Patient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age: an exploratory analysis from the RE-SONANCE study
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články, pozorovací studie
Grantová podpora
N/A
Boehringer Ingelheim GmbH
PubMed
33929686
PubMed Central
PMC8605976
DOI
10.1007/s11239-021-02450-2
PII: 10.1007/s11239-021-02450-2
Knihovny.cz E-zdroje
- Klíčová slova
- Atrial fibrillation, Dabigatran, Non‐vitamin K antagonist oral anticoagulant, Patient perception, Stroke prevention, Warfarin,
- MeSH
- antikoagulancia terapeutické užití MeSH
- aplikace orální MeSH
- cévní mozková příhoda * farmakoterapie MeSH
- dabigatran terapeutické užití MeSH
- fibrilace síní * komplikace diagnóza farmakoterapie MeSH
- fibrinolytika terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- prospektivní studie MeSH
- senioři MeSH
- vitamin K antagonisté a inhibitory MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
- Názvy látek
- antikoagulancia MeSH
- dabigatran MeSH
- fibrinolytika MeSH
- vitamin K MeSH
BACKGROUND: The oral anticoagulant dabigatran offers an effective alternative to vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF), yet patient preference data are limited. The prospective observational RE-SONANCE study demonstrated that patients with AF, newly initiated on dabigatran, or switching to dabigatran from long-term VKA therapy, reported improved treatment convenience and satisfaction compared with VKA therapy. This pre-specified sub-study aimed to assess the impact of country and age on patients' perceptions of dabigatran or VKA therapy in AF. METHODS: RE-SONANCE was an observational, prospective, multi-national study (NCT02684981) that assessed treatment satisfaction and convenience in patients switching from VKAs to dabigatran (Cohort A), or newly diagnosed with AF receiving dabigatran or VKAs (Cohort B), using the PACT-Q questionnaire. Pre-specified exploratory outcomes: variation in PACT-Q2 scores by country and age (< 65, 65 to < 75, ≥ 75 years) (both cohorts); variation in PACT-Q1 responses at baseline by country and age (Cohort B). RESULTS: Patients from 12 countries (Europe/Israel) were enrolled in Cohort A (n = 4103) or B (n = 5369). In Cohort A, mean (standard deviation) PACT-Q2 score increase was highest in Romania (convenience: 29.6 [23.6]) and Hungary (satisfaction: 26.0 [21.4]) (p < 0.001). In Cohort B, mean (standard error) increase in PACT-Q2 scores between dabigatran and VKAs was highest in Romania (visit 3: 29.0 [1.3]; 24.5 [0.9], p < 0.001). Mean PACT-Q2 score increase by age (all p < 0.001) was similar across ages. PACT-Q1 responses revealed lowest expectations of treatment success in Romania and greatest concerns about payment in Estonia, Latvia, and Romania, but were similar across ages. CONCLUSIONS: Treatment satisfaction and convenience tended to favor dabigatran over VKAs. Regional differences in treatment expectations exist across Europe. TRIAL AND CLINICAL REGISTRY: Trial registration number: ClinicalTrials.gov NCT02684981. Trial registration date: February 18, 2016.
1 M Sechenov 1st Moscow State Medical University Moscow Russian Federation
Balassa Janos County Hospital Szekszárd Hungary
Boehringer Ingelheim Pharmaceuticals Inc Ridgefield CT USA
Boehringer Ingelheim RCV GmbH and Co KG Vienna Austria
Faculty of Medicine in Hradec Kralove Charles University and Edumed s r o Broumov Czech Republic
National Cardiology Hospital Sofia Bulgaria
North Estonia Medical Centre Foundation Tallinn Estonia
Pauls Stradins Clinical University Hospital Riga Stradinš University Riga Latvia
Zobrazit více v PubMed
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, ESC Scientific Document Group 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962. doi: 10.1093/eurheartj/ehw210. PubMed DOI
January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, Jr, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation. 2019;140(2):e125–e151. doi: 10.1161/CIR.0000000000000665. PubMed DOI
Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115(21):2689–2696. doi: 10.1161/CIRCULATIONAHA.106.653048. PubMed DOI
Birman-Deych E, Radford MJ, Nilasena DS, Gage BF. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke. 2006;37(4):1070–1074. doi: 10.1161/01.STR.0000208294.46968.a4. PubMed DOI
Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart. 2005;91(4):472–477. doi: 10.1136/hrt.2004.042465. PubMed DOI PMC
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee, Investigators Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. doi: 10.1056/NEJMoa0905561. PubMed DOI
Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbuchel H, ESC Scientific Document Group The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–1393. doi: 10.1093/eurheartj/ehy136. PubMed DOI
Monz BU, Connolly SJ, Korhonen M, Noack H, Pooley J. Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study. Int J Cardiol. 2013;168(3):2540–2547. doi: 10.1016/j.ijcard.2013.03.059. PubMed DOI
Wilke T, Bauer S, Mueller S, Kohlmann T, Bauersachs R. Patient preferences for oral anticoagulation therapy in atrial fibrillation: a systematic literature review. Patient. 2017;10(1):17–37. doi: 10.1007/s40271-016-0185-9. PubMed DOI PMC
De Caterina R, Bruggenjurgen B, Darius H, Kohler S, Lucerna M, Pecen L, Renda G, Schilling RJ, Schliephacke T, Zamorano JL, Le Heuzey JY, Kirchhof P. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: a PREFER in AF Registry substudy. Arch Cardiovasc Dis. 2018;111(2):74–84. doi: 10.1016/j.acvd.2017.04.007. PubMed DOI
Benzimra M, Bonnamour B, Duracinsky M, Lalanne C, Aubert JP, Chassany O, Aubin-Auger I, Mahe I. Real-life experience of quality of life, treatment satisfaction, and adherence in patients receiving oral anticoagulants for atrial fibrillation. Patient Prefer Adherence. 2018;12:79–87. doi: 10.2147/PPA.S131158. PubMed DOI PMC
Vinereanu D, Napalkov D, Bergler-Klein J, Benczur B, Ciernik M, Gotcheva N, Medvedchikov A, Poder P, Simic D, Skride A, Tang W, Trusz-Gluza M, Vesely J, Vishnepolsky T, Vrabec M. Patient perception of anticoagulant treatment for stroke prevention (RE-SONANCE study) Open Heart. 2020;7(1):e001202. doi: 10.1136/openhrt-2019-001202. PubMed DOI PMC
Prins MH, Guillemin I, Gilet H, Gabriel S, Essers B, Raskob G, Kahn SR. Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q) Health Qual Life Outcomes. 2009;7:30. doi: 10.1186/1477-7525-7-30. PubMed DOI PMC
Prins MH, Marrel A, Carita P, Anderson D, Bousser MG, Crijns H, Consoli S, Arnould B. Multinational development of a questionnaire assessing patient satisfaction with anticoagulant treatment: the ‘Perception of Anticoagulant Treatment Questionnaire’ (PACT-Q) Health Qual Life Outcomes. 2009;7:9. doi: 10.1186/1477-7525-7-9. PubMed DOI PMC
Vinereanu D, Lopes RD, Bahit MC, Xavier D, Jiang J, Al-Khalidi HR, He W, Xian Y, Ciobanu AO, Kamath DY, Fox KA, Rao MP, Pokorney SD, Berwanger O, Tajer C, de Barros ESPGM, Roettig ML, Huo Y, Granger CB, IMPACT-AF investigators A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial. Lancet. 2017;390(10104):1737–1746. doi: 10.1016/S0140-6736(17)32165-7. PubMed DOI
Amara W, Larsen TB, Sciaraffia E, Hernandez Madrid A, Chen J, Estner H, Todd D, Bongiorni MG, Potpara TS, Dagres N, Sagnol P, Blomstrom-Lundqvist C. Patients’ attitude and knowledge about oral anticoagulation therapy: results of a self-assessment survey in patients with atrial fibrillation conducted by the European Heart Rhythm Association. Europace. 2016;18(1):151–155. doi: 10.1093/europace/euv317. PubMed DOI
Cimminiello C, Hatala R, Pakarinen S, Friz HP, Fitzmaurice D, Hobbs FR. Non-vitamin k antagonist oral anticoagulants in a European primary care physician survey. BJGP Open. 2018;2(3):bjgpopen18X101602. doi: 10.3399/bjgpopen18X101602. PubMed DOI PMC
ClinicalTrials.gov
NCT02684981
